Average Co-Inventor Count = 4.15
ph-index = 10
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Maxygen, Inc. (10 from 124 patents)
2. Perseid Therapeutics LLC (8 from 8 patents)
3. Merck Sharp + Dohme Corp. (4 from 2,405 patents)
4. Altravax, Inc. (4 from 5 patents)
5. Stategics, Inc. (4 from 4 patents)
6. Astellas Pharma Gmbh (416 patents)
30 patents:
1. 12358986 - Anti-cancer combination therapies comprising CTLA-4 and PD-1 blocking agents
2. 11649290 - CTLA4 binders
3. 10544222 - PD1/CTLA4 binders
4. 10501542 - CTLA4 binders
5. 9657024 - Substituted triazolo-pyrimidine compounds for modulating cell proliferation, differentiation and survival
6. 9186397 - Recombinant dengue virus antigen comprising the capsid protein leader sequence, full-length prM protein, and full-length E protein
7. 9163027 - Substituted triazolo-pyrimidine compounds for modulating cell proliferation differentiation and survival
8. 8715694 - Recombinant dengue virus antigen comprising the capsid protein leader sequence, full-length prM protein, and full-length E protein
9. 8496935 - Immunosuppressive polypeptides and nucleic acids
10. 8491899 - Immunosuppressive polypeptides and nucleic acids
11. 8445230 - Immunosuppressive polypeptides and nucleic acids
12. 8318176 - Immunosuppressive polypeptides and nucleic acids
13. 8283447 - Immunosuppressive polypeptides and nucleic acids
14. 8268587 - Immunosuppressive polypeptides and nucleic acids
15. 8168772 - Nucleic acids encoding novel chimeric C15/prM/E dengue virus immunogens prepared by DNA shuffling